Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease
BackgroundRegarding the complexity of Parkinson's disease (PD), the identification of reliable biomarkers is of great significance for improving the accuracy of diagnosis and monitoring disease progression. Recently, some studies suggested that serum proline-rich protein 14 (PRR14), vascular ce...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2022.993940/full |
| _version_ | 1828173784251629568 |
|---|---|
| author | Huimin Zheng Huimin Zheng Huimin Zheng Huimin Zheng Tai Wang Tai Wang Tai Wang Tai Wang Tai Wang Changhe Shi Changhe Shi Changhe Shi Changhe Shi Liyuan Fan Liyuan Fan Liyuan Fan Liyuan Fan Yun Su Yun Su Yun Su Yun Su Yu Fan Yu Fan Yu Fan Yu Fan Xinwei Li Xinwei Li Xinwei Li Xinwei Li Jing Yang Jing Yang Jing Yang Jing Yang Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Yuming Xu Yuming Xu Yuming Xu Yuming Xu |
| author_facet | Huimin Zheng Huimin Zheng Huimin Zheng Huimin Zheng Tai Wang Tai Wang Tai Wang Tai Wang Tai Wang Changhe Shi Changhe Shi Changhe Shi Changhe Shi Liyuan Fan Liyuan Fan Liyuan Fan Liyuan Fan Yun Su Yun Su Yun Su Yun Su Yu Fan Yu Fan Yu Fan Yu Fan Xinwei Li Xinwei Li Xinwei Li Xinwei Li Jing Yang Jing Yang Jing Yang Jing Yang Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Yuming Xu Yuming Xu Yuming Xu Yuming Xu |
| author_sort | Huimin Zheng |
| collection | DOAJ |
| description | BackgroundRegarding the complexity of Parkinson's disease (PD), the identification of reliable biomarkers is of great significance for improving the accuracy of diagnosis and monitoring disease progression. Recently, some studies suggested that serum proline-rich protein 14 (PRR14), vascular cell adhesion molecule-1 (VCAM-1), and soluble CD163 (sCD163) factors may be associated with PD, even as potential biomarkers. However, the role of these serum factors is still unclear.ObjectivesThis study aimed to explore the alterations of serum PRR14, VCAM-1, and sCD163 levels during PD progression, and their association with disease-related variables of PD.MethodsWe performed the assessment of scale tests and the detection of serum samples in patients with PD (n = 100) and healthy controls (HCs, n = 100). Furthermore, we investigated the association between serum factors and sex, cognitive impairments, H&Y (Hohn and Yahr), age at onset (AAO), and other variables in patients with PD.ResultsPatients with PD exhibited increased PRR14 and VCAM-1 serum levels compared with HCs. No significant differences were found in serum levels of sCD163. Subgroup analysis uncovered increased VCAM-1 in the female and male subgroups (PD and HCs). Among patients with PD, decreased PRR14 and increased VCAM-1 were associated with severer cognitive impairments and severer PD (H&Y), respectively. Bivariate correlation analysis revealed that there was a positive correlation between VCAM-1 and AAO.ConclusionsIncreased serum levels of PRR14 and VCAM-1 suggest that inflammation and defective autophagy may play vital roles in the pathogenesis of PD. However, the potential mechanisms remain to be elucidated. |
| first_indexed | 2024-04-12T04:01:05Z |
| format | Article |
| id | doaj.art-db3b107ef88348778b870786d5cbb436 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-12T04:01:05Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-db3b107ef88348778b870786d5cbb4362022-12-22T03:48:42ZengFrontiers Media S.A.Frontiers in Neurology1664-22952022-09-011310.3389/fneur.2022.993940993940Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's diseaseHuimin Zheng0Huimin Zheng1Huimin Zheng2Huimin Zheng3Tai Wang4Tai Wang5Tai Wang6Tai Wang7Tai Wang8Changhe Shi9Changhe Shi10Changhe Shi11Changhe Shi12Liyuan Fan13Liyuan Fan14Liyuan Fan15Liyuan Fan16Yun Su17Yun Su18Yun Su19Yun Su20Yu Fan21Yu Fan22Yu Fan23Yu Fan24Xinwei Li25Xinwei Li26Xinwei Li27Xinwei Li28Jing Yang29Jing Yang30Jing Yang31Jing Yang32Chengyuan Mao33Chengyuan Mao34Chengyuan Mao35Chengyuan Mao36Chengyuan Mao37Yuming Xu38Yuming Xu39Yuming Xu40Yuming Xu41Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, Nanyang Central Hospital, Nanyang, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaInstitute of Neuroscience, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaInstitute of Neuroscience, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaThe Academy of Medical Sciences of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaInstitute of Neuroscience, Zhengzhou University, Zhengzhou, ChinaDepartment of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaHenan Key Laboratory of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaNHC Key Laboratory of Prevention and Treatment of Cerebrovascular Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaInstitute of Neuroscience, Zhengzhou University, Zhengzhou, ChinaBackgroundRegarding the complexity of Parkinson's disease (PD), the identification of reliable biomarkers is of great significance for improving the accuracy of diagnosis and monitoring disease progression. Recently, some studies suggested that serum proline-rich protein 14 (PRR14), vascular cell adhesion molecule-1 (VCAM-1), and soluble CD163 (sCD163) factors may be associated with PD, even as potential biomarkers. However, the role of these serum factors is still unclear.ObjectivesThis study aimed to explore the alterations of serum PRR14, VCAM-1, and sCD163 levels during PD progression, and their association with disease-related variables of PD.MethodsWe performed the assessment of scale tests and the detection of serum samples in patients with PD (n = 100) and healthy controls (HCs, n = 100). Furthermore, we investigated the association between serum factors and sex, cognitive impairments, H&Y (Hohn and Yahr), age at onset (AAO), and other variables in patients with PD.ResultsPatients with PD exhibited increased PRR14 and VCAM-1 serum levels compared with HCs. No significant differences were found in serum levels of sCD163. Subgroup analysis uncovered increased VCAM-1 in the female and male subgroups (PD and HCs). Among patients with PD, decreased PRR14 and increased VCAM-1 were associated with severer cognitive impairments and severer PD (H&Y), respectively. Bivariate correlation analysis revealed that there was a positive correlation between VCAM-1 and AAO.ConclusionsIncreased serum levels of PRR14 and VCAM-1 suggest that inflammation and defective autophagy may play vital roles in the pathogenesis of PD. However, the potential mechanisms remain to be elucidated.https://www.frontiersin.org/articles/10.3389/fneur.2022.993940/fullParkinson's diseaseproline-rich protein 14vascular cell adhesion molecule-1soluble CD163serum |
| spellingShingle | Huimin Zheng Huimin Zheng Huimin Zheng Huimin Zheng Tai Wang Tai Wang Tai Wang Tai Wang Tai Wang Changhe Shi Changhe Shi Changhe Shi Changhe Shi Liyuan Fan Liyuan Fan Liyuan Fan Liyuan Fan Yun Su Yun Su Yun Su Yun Su Yu Fan Yu Fan Yu Fan Yu Fan Xinwei Li Xinwei Li Xinwei Li Xinwei Li Jing Yang Jing Yang Jing Yang Jing Yang Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Chengyuan Mao Yuming Xu Yuming Xu Yuming Xu Yuming Xu Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease Frontiers in Neurology Parkinson's disease proline-rich protein 14 vascular cell adhesion molecule-1 soluble CD163 serum |
| title | Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease |
| title_full | Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease |
| title_fullStr | Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease |
| title_full_unstemmed | Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease |
| title_short | Increased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease |
| title_sort | increased prr14 and vcam 1 level in serum of patients with parkinson s disease |
| topic | Parkinson's disease proline-rich protein 14 vascular cell adhesion molecule-1 soluble CD163 serum |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2022.993940/full |
| work_keys_str_mv | AT huiminzheng increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT huiminzheng increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT huiminzheng increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT huiminzheng increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT taiwang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT taiwang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT taiwang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT taiwang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT taiwang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT changheshi increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT changheshi increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT changheshi increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT changheshi increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT liyuanfan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT liyuanfan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT liyuanfan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT liyuanfan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yunsu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yunsu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yunsu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yunsu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yufan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yufan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yufan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yufan increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT xinweili increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT xinweili increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT xinweili increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT xinweili increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT jingyang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT jingyang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT jingyang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT jingyang increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT chengyuanmao increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT chengyuanmao increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT chengyuanmao increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT chengyuanmao increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT chengyuanmao increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yumingxu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yumingxu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yumingxu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease AT yumingxu increasedprr14andvcam1levelinserumofpatientswithparkinsonsdisease |